PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results - John - 2020 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - Abstract - Europe PMC
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device - ScienceDirect
Supplementary Appendix 2020.01.27 R2
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
Longâ•'term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | SpringerLink
PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa - Santagostino - 2014 - Haemophilia - Wiley Online Library
